Who Actually Pays? Reimbursement and Payer Strategy for Digital Health PMs

In healthcare, the person who uses your product, the person who champions it internally, and the person who cuts the check are usually three separate humans with three separate incentives. A clinician can love your remote monitoring tool, a CMO can approve the pilot, and the whole thing still dies if no payer — Medicare, a commercial insurer, or an employer — will reimburse for it. Reimbursement strategy isn't finance's problem to solve after launch; it's a product requirement that determines your feature roadmap from day one.

Quick Answer: Digital health products get paid for through three structurally different paths — fee-for-service billing codes (CPT/HCPCS), value-based contracts tied to outcomes, or direct payment from employers and consumers. Each path dictates a different set of features, evidence, and stakeholders you must win before a single dollar arrives.

Why "Who Pays" Is Three Different Questions in Healthcare

The user, the buyer, and the payer are rarely the same person, and conflating them is the single most common strategic error healthtech PMs make. A clinician using your tool is the user. The health system's VP of digital health or informatics who signs the contract is the buyer. The entity that ultimately transfers money — Medicare, an insurer, an employer, or the patient's own wallet — is the payer.

These roles can diverge so far that optimizing for one actively works against another:

• User wants less clicking, faster documentation, fewer alerts.
• Buyer wants lower total cost of ownership, integration with existing systems, and a defensible ROI story to their own board.
• Payer wants proof the intervention changes a clinical or financial outcome enough to justify reimbursement, whether that's a CPT code, a shared-savings contract, or a self-insured employer's claims trend.

A product roadmap built only around user delight will accumulate features the payer never asked for and won't fund. This is why reimbursement modeling belongs next to your customer journey mapping work, not bolted on afterward — the payment mechanism is itself a stage in the journey, often the stage where deals actually die. For teams still building foundational fluency in this market, our complete guide to healthtech product management covers the regulatory and stakeholder landscape this article assumes.

The Three Payer Archetypes

Fee-for-Service: CPT, HCPCS, and RPM Codes That Shape Your Feature Set

Fee-for-service reimbursement pays for a defined, codified service — meaning the CPT or HCPCS code's exact requirements become your product's minimum viable feature set, not a suggestion. If the code requires 16 days of transmitted data, your product must reliably capture and transmit data on at least 16 days or the claim is deniable. This is the most concrete, and most constraining, monetization path in healthcare.

Remote patient monitoring (RPM) is the clearest teaching example because the Centers for Medicare & Medicaid Services (CMS) publishes exact rules that translate directly into engineering requirements. CMS created a family of RPM codes specifically to reimburse the collection and clinical review of physiologic data, and the fine print of each code is effectively a product spec written by the federal government.

The RPM Code Family, Decoded as Product Requirements

Notice what this table teaches: none of these codes reimburse for "monitoring" in the abstract. They reimburse for specific, auditable behaviors — a 16-day transmission threshold, a 20-minute review increment, a documented setup encounter. A PM who treats RPM as "just send vitals to a dashboard" will ship a product that cannot generate a billable claim, no matter how clinically useful it is.

This is also where compliance and reimbursement collide. Every data point that supports a claim is protected health information, which means your RPM build inherits the same obligations covered in HIPAA for product managers — audit trails, minimum necessary access, and business associate agreements aren't optional scaffolding around the billing logic, they're load-bearing.

Practical rule: before scoping any fee-for-service digital health feature, read the actual CMS code descriptor and local coverage determination, not a summary of it. Build your acceptance criteria directly from the descriptor's language.

Value-Based Care: When You're Selling Outcomes, Not Encounters

Value-based contracts pay for an outcome or a shared-savings result rather than a discrete billable event, which shifts the product requirement from "did the workflow happen" to "did the population-level metric move." This is a fundamentally different evidence bar, and it usually takes longer to prove than a fee-for-service claim takes to file.

Under models like Medicare Shared Savings Program Accountable Care Organizations (ACOs) or commercial risk-based contracts, a health system is paid based on total cost of care and quality metrics across an attributed population, not per service rendered. Your product succeeds financially only if it measurably bends a cost curve or improves a quality measure the contract already tracks — readmission rates, HEDIS measures, ED utilization.

Three things change when you're building for value-based reimbursement instead of fee-for-service:

1. The unit of success is a cohort, not an encounter. You need population-level analytics and risk stratification, not just individual patient screens.
2. The proof cycle is long. Outcomes like reduced 30-day readmissions or avoided hospitalizations take months of trailing claims data to confirm — plan your evidence roadmap around quarterly or annual measurement windows, not sprint cycles.
3. The buyer becomes the risk-bearing entity itself, often a health system's population health or ACO leadership team, who cares about actuarial trend lines more than individual clinician satisfaction.

Research bodies like the NEJM Catalyst and health policy trackers such as the Peterson-KFF Health System Tracker have repeatedly documented that value-based arrangements still cover a minority of U.S. healthcare spend relative to fee-for-service, and that the transition has been slower and more uneven across markets than early ACO advocates predicted. That gap is strategically important: it means most digital health products still need a credible fee-for-service or hybrid path even if value-based care is the long-term bet.

Employer and Direct-to-Consumer Models: Skipping the Payer Entirely

Employer-sponsored and direct-to-consumer models let you bypass traditional payer adjudication by selling directly to a self-insured employer's benefits budget or to the patient's own wallet, trading a lower evidence bar for a much smaller, more price-sensitive check. This is often the fastest path to first revenue in digital health, which is exactly why it's popular with earlier-stage teams.

Employer-sponsored deals sell into HR and benefits leadership, frequently brokered through a benefits consultant. The decision-maker cares about employee engagement, utilization, and a directionally credible cost-avoidance story — not necessarily peer-reviewed clinical trial data. Sector research from organizations like Rock Health, which has tracked digital health funding and deal structures for over a decade, has consistently shown employer and health-plan channels as major go-to-market routes for point-solution digital health companies, precisely because the sales cycle is shorter than payer contracting.

Direct-to-consumer (DTC) models remove the intermediary entirely: the patient pays out of pocket or through an HSA/FSA. The evidence bar shifts again — from clinical proof to perceived value and willingness to pay. This is closer to a classic consumer product problem, which is why applying Jobs to Be Done thinking — what job is the patient hiring this product to do, and what's the anxiety of the status quo they're paying to relieve — often predicts DTC traction better than a clinical outcomes deck does.

The trade-off across all three non-fee-for-service paths is durability. Employer contracts renew annually and are vulnerable to a single benefits-consultant relationship changing. DTC revenue is sensitive to price and churns fast if the perceived value dips. Neither gives you the multi-year predictability a payer contract or an established CPT code can.

The Decision Map: From Monetization Model to Required Evidence

Every monetization model implies a specific evidence package and a specific stakeholder you must convert before revenue starts flowing — treat this as a lookup table you consult before writing a single PRD, not a retrospective justification. Get the mapping backwards — building the evidence a value-based contract needs while pitching a fee-for-service buyer — and you'll have the right proof for the wrong conversation.

Applied to the RPM example from earlier: if your monetization model is CMS fee-for-service RPM codes, the feature you cannot skip is transmission-day counting and clinician time logging — full stop, regardless of how compelling your dashboard UX is. If instead you're selling into a value-based ACO, that same RPM data pipeline needs to roll up into readmission and utilization trend reporting for a population, and the 16-day transmission threshold matters far less than whether the aggregate cohort trend moves.

This is also where clinical safety and monetization intersect. A feature built to satisfy a value-based outcome claim — say, an AI model flagging deterioration risk — inherits the scrutiny covered in AI clinical decision support safety, because a payer or health system will ask how the model was validated before crediting it with the outcome improvement you're claiming.

Winning the Stakeholder Who Actually Controls the Purse

Every monetization path above routes through a different internal champion, and misreading who actually controls budget is as common a failure mode as misreading the code requirements. A clinical champion can love your product and still have zero authority over whether a value-based contract line item gets renewed. A compliance officer who never touches the UI can single-handedly block a fee-for-service launch over documentation gaps.

Because your product typically sits at the intersection of a clinician's daily workflow and a patient's data, it's also worth revisiting how those two very different users experience the same reimbursement-driven feature — the discipline covered in clinician vs. patient dual-user design — since a feature built purely to satisfy a billing code can quietly degrade the experience for either side if you're not deliberate about it.

Key Takeaways

• The user, buyer, and payer are usually three different people in healthcare, and a product built only for user delight can still fail commercially.
• Fee-for-service CPT/HCPCS codes function as a product spec: RPM codes like 99453, 99454, 99457, and 99091 each imply a specific, auditable feature (transmission-day counts, clinician time logs) that must be built before a claim can be filed.
• Value-based contracts pay for population outcomes over a long measurement window, requiring cohort-level analytics and patience that fee-for-service billing doesn't demand.
• Employer and direct-to-consumer models skip payer adjudication in exchange for a lower evidence bar, a shorter sales cycle, and less contract durability.
• Match your evidence package to your monetization model before you scope features — the decision map from model to required proof to stakeholder is a lookup table, not an afterthought.
• Reimbursement-driven features still carry HIPAA and clinical-safety obligations, since the data proving a claim or an outcome is protected health information reviewed by real clinical stakeholders.
• Tracking the payer, provider, and administrator relationship web deliberately — with a tool designed for alignment tracking rather than a stale spreadsheet — reduces the chance a critical approver relationship quietly lapses.